A patient suffering from Duchenne muscular dystrophy died after undergoing a gene-editing therapy in China, raising significant concerns regarding regulatory oversight in the biotech sector. The developer, HuidaGene Therapeutics, reported that the patient, a young boy, succumbed to acute respiratory distress syndrome due to a severe immune response to the treatment. This incident follows investigative reports into multiple trials, including another recent death in a different trial, prompting Chinese authorities to initiate investigations into the safety and transparency of such therapies as China aims to bolster its biotechnology leadership.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://timesofindia.indiatimes.com/world/china/patient-dies-in-china-biotech-companys-gene-editing-trial/articleshow/133018924.cms
